Global Diverticular Disease Market, By Type (Diverticulosis, Diverticulitis, and Diverticular Bleeding), Treatment (Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, and IV fluids), Diagnosis (Barium X-ray, CT scan, Liver function test, Blood test, Urine test, and Ultrasound), Symptoms (Abdominal Pain, Fever, Constipation, Bloating, Nausea, Diarrhea, and Others), Dosage (Tablet, Injection, and Others), Route of Administration (Oral, Intravenous, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031.
Diverticular Disease Market Analysis and Size
Diverticular disease market is advancing with innovations in diagnostic tools such as CT scans for precise detection. Treatment focuses on dietary adjustments, antibiotics for infections, and occasionally surgery for complications. Technological advancements include minimally invasive procedures such as endoscopic therapy. The market growth is fueled by aging populations and dietary changes, highlighting a shift towards non-surgical interventions for managing this prevalent gastrointestinal condition.
The global diverticular disease market size was valued at USD 1.69 billion in 2023 and is projected to reach USD 3.19 billion by 2031, with a CAGR of 8.27% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Diverticulosis, Diverticulitis, and Diverticular Bleeding), Treatment (Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, and IV fluids), Diagnosis (Barium X-ray, CT scan, Liver function test, Blood test, Urine test, and Ultrasound), Symptoms (Abdominal Pain, Fever, Constipation, Bloating, Nausea, Diarrhea, and Others), Dosage (Tablet, Injection, and Others), Route of Administration (Oral, Intravenous, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Melinta Therapeutics LLC (U.S.), Nabriva Therapeutics plc (Ireland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (Netherlands), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Lupin (India), and AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Diverticular disease refers to the condition where small pouches (diverticula) form in the lining of the digestive system, typically in the colon. These pouches can become inflamed or infected, leading to symptoms such as abdominal pain, bloating, constipation, or diarrhea. Treatment often involves dietary adjustments, medications to relieve symptoms, and, in severe cases, surgery to remove affected portions of the colon.
Diverticular Disease Market Dynamics
Drivers
- Patient Preference for Non-invasive Treatments
The diverticular disease market is driven by increasing patient preference for non-invasive treatments such as dietary adjustments, medications, and lifestyle changes. For instance, dietary fiber supplements and probiotics are increasingly favored for managing symptoms and preventing flare-ups, reflecting a shift towards holistic management approaches. This trend not only enhances patient compliance but also fuels demand for innovative, non-surgical solutions, shaping the market towards more effective and patient-centric care strategies.
- Increasing Prevalence of Obesity
The rising global prevalence of obesity has become a significant driver for the diverticular disease market. Obesity is strongly associated with increased rates of diverticulosis and diverticulitis due to its impact on digestive health. As obesity rates climb, so does the incidence of these conditions, prompting greater demand for diagnostic tools, treatments, and management strategies. This trend underscores the market's growth as healthcare systems respond to the escalating burden of obesity-related digestive disorders.
Opportunities
- Technological Advancements in Treatment
Technological advancements in minimally invasive surgical techniques and pharmaceutical therapies have revolutionized the treatment landscape for diverticular disease. For instance, procedures such as laparoscopic sigmoid colectomy offer reduced recovery times and lower complication rates compared to traditional open surgeries. Similarly, new pharmaceutical therapies such as targeted antibiotics and anti-inflammatory agents provide more tailored and effective treatment options, enhancing patient outcomes and driving growth opportunities in the diverticular disease market.
- Increasing Research and Development
Ongoing research into the pathophysiology and treatment of diverticular disease is creating opportunities in the market by fostering the development of novel therapies and management strategies. For instance, studies exploring probiotics' efficacy in preventing diverticulitis recurrence or investigating the role of dietary modifications in symptom management are paving the way for innovative treatments. These advancements not only enhance patient outcomes but also expand the market potential for effective interventions in diverticular disease management.
Restraints/Challenges
- High Treatment Costs
High treatment costs for diverticular disease, necessitating long-term medication, dietary adjustments, and potential surgical interventions in severe cases, pose significant barriers. These expenses can be financially burdensome for patients and strain healthcare systems, hindering market growth.
- Limited Treatment Options
The diverticular disease market faces constraints due to limited pharmacological treatments, which focus on symptom management rather than curing the condition. This limitation restricts revenue growth potential as existing treatments do not address the underlying cause of the disease. As a result, healthcare providers and patients are limited in their options for effectively treating and managing diverticular disease, impacting market dynamics and growth prospects.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Emmaus Life Sciences began preliminary studies focusing on diverticulitis treatment, marking the first patient enrollment for their research initiative. The company aimed to advance understanding and therapeutic options in this area
- In 2020, Hikma Pharmaceuticals PLC introduced a Dicyclomine Hydrochloride oral solution. This innovation aimed to enhance treatment efficacy for a range of inflammatory bowel diseases, addressing diverse diagnostic challenges within the field
Diverticular Disease Market Scope
The market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Diverticulosis
- Diverticulitis
- Diverticular Bleeding
Treatment
- Medications
- Surgery
- Supportive care
- Penicillin Antibiotic
- Antibiotics
- Dietary Supplements
- IV fluids
Diagnosis
- Barium X-ray
- CT scan
- Liver function test
- Blood test
- Urine test
- Ultrasound
Symptoms
- Abdominal Pain
- Fever
- Constipation
- Bloating
- Nausea
- Diarrhea
- Others
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Diverticular Disease Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the diverticular disease market, fueled by rising disease awareness, significant key player presence, high disposable incomes, and a well-developed healthcare infrastructure. These factors position the region at the forefront of advancements and treatment accessibility for this gastrointestinal condition.
Asia-Pacific is expected to show significant growth in the diverticular disease market, driven by increasing research and development activities, rising investment in the healthcare sector, and growing government support. These factors are poised to enhance treatment options and improve patient outcomes across the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Diverticular Disease Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Melinta Therapeutics LLC (U.S.)
- Nabriva Therapeutics plc (Ireland)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (Netherlands)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Lupin (India)
- AbbVie Inc. (U.S.)
SKU-